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SAP domain-dependent Mkl1 signaling stimulates
proliferation and cell migration by induction of a
distinct gene set indicative of poor prognosis in
breast cancer patients
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Abstract
Background: The main cause of death of breast cancer patients is not the primary tumor itself but the metastatic
disease. Identifying breast cancer-specific signatures for metastasis and learning more about the nature of the genes
involved in the metastatic process would 1) improve our understanding of the mechanisms of cancer progression
and 2) reveal new therapeutic targets. Previous studies showed that the transcriptional regulator megakaryoblastic
leukemia-1 (Mkl1) induces tenascin-C expression in normal and transformed mammary epithelial cells. Tenascin-C is
known to be expressed in metastatic niches, is highly induced in cancer stroma and promotes breast cancer
metastasis to the lung.
Methods: Using HC11 mammary epithelial cells overexpressing different Mkl1 constructs, we devised a subtractive
transcript profiling screen to identify the mechanism by which Mkl1 induces a gene set co-regulated with
tenascin-C. We performed computational analysis of the Mkl1 target genes and used cell biological experiments to
confirm the effect of these gene products on cell behavior. To analyze whether this gene set is prognostic of
accelerated cancer progression in human patients, we used the bioinformatics tool GOBO that allowed us to
investigate a large breast tumor data set linked to patient data.
Results: We discovered a breast cancer-specific set of genes including tenascin-C, which is regulated by Mkl1 in a
SAP domain-dependent, serum response factor-independent manner and is strongly implicated in cell proliferation,
cell motility and cancer. Downregulation of this set of transcripts by overexpression of Mkl1 lacking the SAP domain
inhibited cell growth and cell migration. Many of these genes are direct Mkl1 targets since their promoter-reporter
constructs were induced by Mkl1 in a SAP domain-dependent manner. Transcripts, most strongly reduced in the
absence of the SAP domain were mechanoresponsive. Finally, expression of this gene set is associated with
high-proliferative poor-outcome classes in human breast cancer and a strongly reduced survival rate for patients
independent of tumor grade.
Conclusions: This study highlights a crucial role for the transcriptional regulator Mkl1 and its SAP domain during
breast cancer progression. We identified a novel gene set that correlates with bad prognosis and thus may help in
deciding the rigor of therapy.
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Most breast cancer patients die from tumor metastases
and not from the primary tumor itself. Thus, the identi-
fication of genes and signaling pathways influencing the
metastatic process are of utmost importance. Once the
mechanisms leading to metastasis are uncovered, they
can in the future serve as a rational basis for prognosis
and intervention. From the beginning of its discovery,
tenascin-C has been strongly associated with tumorigen-
esis and cancer progression in many different types of
tumors (reviewed in [1,2]). Tenascin-C was not only
enriched in breast cancer tissue [3,4], but its high ex-
pression was part of a gene signature of breast cancers
metastasizing to the lung [5]. There is strong evidence
that tenascin-C contributes to the metastatic behavior of
breast cancer cells [6] by providing a niche for their
settlement in the lung [7,8]. The source of tenascin-C
can be the tumor cells themselves as well as the stromal
cells of the cancer microenvironment. Downregulation
of tenascin-C by miR-335 or shRNA in human cancer
cells in a mouse xenograft model inhibits metastasis for-
mation [7], and in tenascin-C-deficient mice, metastasis
formation of tenascin-C positive cancer cells is also
suppressed [9].
There are many signaling pathways inducing tenascin-C
expression (reviewed in [10]). Among these, mechanical
strain application in vivo as well as to cells in culture is
a potent stimulus to induce tenascin-C expression in fi-
broblasts [11,12]. We have recently shown that induc-
tion of tenascin-C by cyclic mechanical strain requires
the action of Mkl1 [13]. Mkl1 is a member of the
myocardin-related transcription factor family (MRTF)
and a well-known transcriptional co-activator of serum
response factor (SRF) [14-16]. SRF target genes, which
are regulated upon recruitment of MRTF cofactors, en-
code proteins involved in actin cytoskeletal function
that can either be structural (for example, actin) or re-
lated to actin dynamics (for example, talin 1) (reviewed
in [17,18]). However, Mkl1-mediated stretch-induced
tenascin-C expression in fibroblasts did not require
SRF, but instead depended on the potential DNA-
binding SAP domain of Mkl1. This implies a novel
mode of Mkl1 action as a bona fide transcription factor
in mechanotransduction [13]. Interestingly, normal and
transformed mouse mammary epithelial cells also ap-
pear to be highly sensitive to Mkl1 signaling, respond-
ing to Mkl1 overexpression with several fold induction
of tenascin-C [13].
The present study was designed to find SAP-dependent
Mkl1 target genes co-regulated with tenascin-C and to
analyze whether such genes could be indicative of specific
physiological states of cells that might be controlled by
mechanotransduction. For our study, we made use of the
HC11 mammary epithelial cell line. HC11 cells are capable
of both self-renewal and differentiation and can be cul-
tured for unlimited time in an undifferentiated state [19],
the condition we used in our study. HC11 cells can recon-
stitute the ductal epithelium of a cleared mammary fat
pad in vivo with ductal, alveolar and myoepithelial cells,
illustrating their stem cell abilities [19,20]. In addition,
HC11 cells contain a mutated p53 gene that not only in-
creases the replicative potential of stem cells but confers
predisposition to mammary carcinoma [21]. Undifferen-
tiated HC11 cells share transcriptome signatures with
human breast cancer [22], supporting the relevance of
this model for breast cancer-related studies. We there-
fore concluded our study by investigating whether the
genes co-regulated with tenascin-C would also be impli-
cated in breast cancer progression.
Results
Screen for SAP-dependent Mkl1 target genes
We devised a screening method to identify genes co-
regulated with tenascin-C by Mkl1 in a SAP domain-
dependent manner without involvement of SRF. For this
purpose, we used HC11 mammary epithelial cells that
react strongly to the overexpression of Mkl1 with in-
duction of tenascin-C expression [13]. We compared
three HC11 strains that either overexpress the C-terminal
red fluorescent protein (RFP)-tagged full length Mkl1
(HC11-FL), Mkl1-RFP with a mutated SRF-interaction site
(HC11-mutB1) or Mkl1-RFP with a deletion of the SAP
domain (HC11-ΔSAP). None of the three Mkl1 variants
appear to be toxic to the cells, as we have not observed
any changes in viability or cell morphology. HC11-FL cells
were shown to overexpress Mkl1 7.1-fold above the en-
dogenous Mkl1 present in parental HC11 cells [13], and
were used as control cells in our study. All cell strains
were FACS sorted to express similar levels of Mkl1-RFP
proteins. These cells were used for transcript profiling
and gene lists of interest were established as shown in
Figure 1A, B. A scatter plot (Figure 1A) of all transcripts
e x p r e s s e di nH C 1 1 - m u t B 1v e r sus HC11-FL control cells
(y-axis) and all transcripts expressed in HC11-ΔSAP
versus HC11-FL control cells (x-axis) shows that a large
majority of transcripts does not differ significantly be-
tween the three cell strains (log fold change (FC)≈ 0;
black dots). Setting the threshold to a 2-fold reduction
(logFC= -1; grey lines), three gene sets can be distin-
guished: 1) blue dots represent genes that are lower in
HC11-mutB1 than in HC11-FL control cells, but are
unaffected in HC11-ΔSAP cells, thus representing typ-
ical SRF/Mkl1 target genes; 2) green dots represent
genes that are lower in HC11-ΔSAP than in HC11-FL
control cells, but are unaffected in HC11-mutB1 cells
(this gene set includes tenascin-C); and 3) red dots indi-
cate genes with reduced expression in both HC11-mutB1
and HC11-ΔSAP cells compared to HC11-FL control cells.
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that were distinct from the large majority of transcripts
and were dependent for expression on the B1 site of
Mkl1, the SAP domain, or both. The three groups pre-
sented by a Venn diagram (Figure 1B) contain 141 pro-
besets for transcripts that depended on the function of
the B1 site but not the SAP domain for their induction,
113 probesets for transcripts that depended on both of
these Mkl1 domains and a third group of 205 probesets
for transcripts co-regulated with tenascin-C that did not
require an interaction of Mkl1 with SRF but depended
on the SAP domain for induction (complete probeset
lists and annotations are found in Additional file 1:
Table S1, Additional file 2: Table S2 and Additional file 3:
Table S3). This analysis revealed that the SAP-dependent
mechanism of tenascin-C regulation by Mkl1 is shared
by a large cohort of genes. Below the Venn diagram, we
indicated which cells were deficient in the respective
transcripts. Thus, the typical SRF/Mkl1 target genes are re-
duced in HC11-mutB1 cells, while the SRF-independent/
SAP-dependent genes are reduced in HC11-ΔSAP cells.
The intermediate group that requires both Mkl1 activities
is reduced in both the HC11-mutB1 and HC11-ΔSAP
cells.
The SAP-dependent Mkl1 target genes are implicated in
cancer
Functional analysis of the three gene lists using the
IPA software revealed different molecular and cellular
functions (Figure 1C) and different disease associations
(Figure 1D) for the three types of gene signatures. Thus,
the SRF-dependent/SAP-independent signature implicated
a function of these genes in cellular movement and the
linked diseases included connective tissue disorders, in-
flammatory disease and skeletal and muscle disorders,
which are the main features known to be regulated by
SRF/Mkl1 interaction [23-25]. The SRF-dependent/SAP-
dependent group of genes includes as major functions
post-translational modification, protein degradation and
protein synthesis, and the top disease association is cancer.
Finally, the genes of the SRF-independent/SAP-dependent
group were associated with extremely high significance
with cell cycle and cancer (-logP≥25 and≥30, respect-
ively), while the SRF/Mkl1 target genes were associated
with the same two categories at low significance only
(-logP≥2a n d ≥7, respectively). These data imply that
SAP-dependent induction of transcription by Mkl1 may
counteract the known differentiation-promoting effect of
SRF/Mkl1-induced transcription. A list of SAP-dependent
genes with published cancer-related functions, whose
transcripts were downregulated more than 3-fold in
HC11-ΔSAP compared to HC11-FL control cells, is pre-
sented in Table 1. To confirm that these transcripts are
indeed differentially expressed in the different HC11
cell strains, qRT-PCR analysis was performed using
cDNA from three different batches of the respective
HC11 strains. Differences in gene expression between
HC11-ΔSAP and control cells are presented in Table 1
and in more detail in Additional file 4: Figure S1. The
qRT-PCR results agreed with the data obtained by tran-
script profiling. We also tested the SAP-dependent gene
expression in the HC11 strains when grown in the pres-
ence of serum. It is interesting to note that in the presence
of 3% FCS, these transcripts remained strongly reduced in
HC11-ΔSAP compared to control cells (Table 1). Thus,
the induction of these genes seems to depend mainly on
whether the SAP domain is present in the transfected
Mkl1 construct.
In addition, we monitored changes in the expression
of some of the SRF-independent/SAP-dependent Mkl1
targets on a protein level. In agreement with the changes
seen at the transcript level, we confirmed the reduction
of tenascin-C, Wisp1 and Nox4 proteins in cells overex-
pressing the ΔSAP-Mkl1 construct compared to the
HC11-FL control and HC11-mutB1 cells (Additional file 4:
Figure S2). Using zymography, we found that Mmp2, a
gene that was not affected by Mkl1 overexpression at
the transcript level was highly expressed in all three cell
strains, whereas Mmp3 and/or 12, which belonged to
the SRF-dependent/SAP-dependent gene set, were al-
most completely lacking in HC11-mutB1 as well as
HC11-ΔSAP cells, corresponding to the data obtained
by transcript profiling.
(See figure on previous page.)
Figure 1 Screen for SAP-dependent Mkl1 target genes and their implication in cancer. (A) Scatter plot and (B) Venn diagram representing
classification of Mkl1 target genes into three groups: SRF-dependent/SAP-independent (blue), SRF-dependent/SAP-dependent (red) and
SRF-independent/SAP-dependent (green). The scatter plot (A) represents the log fold change (logFC) in gene expression in HC11-ΔSAP versus
HC11-FL control cells (x-axis; ΔSAP vs. FL) and between HC11-mutB1 versus HC11-FL control cells (y-axis; mutB1 vs. FL). Each dot represents a
probeset, and the one for tenascin-C is highlighted (Tnc). The vertical and horizontal lines in the chart denote the 2-fold change cutoff (logFC
=-1). The Venn diagram (B) represents the number of probesets for transcripts, which are more than 2-fold reduced in either HC11-mutB1 or
HC11-ΔSAP cells when compared to HC11-FL control cells. Boxes below the Venn diagram indicate the cell strains that have reduced levels of
the respective transcripts. (C, D) Functional analysis for the three Mkl1-regulated gene sets performed using the IPA software. The high-level
functional (C) and disease (D) categories are displayed along the x-axis of each bar chart. The y-axis displays the –log of the P-value determined
by right-tailed Fisher’s exact test. The P-value is a measure of the likelihood that the association between a set of genes in each dataset and a
related function or disease is due to random association. The grey vertical line denotes the cutoff for significance (P=0.05; -logP= 1.3).
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direct Mkl1 target genes
Since we have previously shown that the SAP domain of
Mkl1 interacts with the proximal promoter of tenascin-C
to induce its transcription [13], we tested whether this was
also the case for other transcripts of the same group.
The promoters of the SRF-independent/SAP-dependent
genes listed in Table 1 encompassing at least 500 bp up-
stream of the transcription start site (TSS) were fused
to the secreted alkaline phosphatase (SEAP) reporter
gene of pSEAP2-Basic. We tested the induction of each
promoter-reporter construct by co-transfection with FL-
Mkl1 (Figure 2A). This revealed that the majority of the
new promoters tested (8 out of 12) were induced at least
2-fold by Mkl1 in comparison to co-transfection with
an inactive Mkl1 devoid of thet r a n s a c t i v a t i o nd o m a i n ,
indicating that these are indeed direct Mkl1 target
genes. The promoter constructs that did not respond to
Mkl1 overexpression may represent genes that are in-
directly regulated by Mkl1, or the relevant promoter
regions were not contained in the constructs tested.
Next, we investigated whether the induction was SAP-
dependent and SRF-independent by comparing the re-
porter activity after co-transfection with mutB1- versus
ΔSAP-Mkl1 variants (Figure 2B). Indeed, the promoter-
reporter constructs induced by FL-Mkl1 were also
strongly induced by mutB1-Mkl1, but not by ΔSAP-Mkl1.
In contrast, the promoter const r u c tf o rA c t a 2 ,ag e n ef r o m
the SRF-dependent/SAP-independent gene set was strongly
induced by ΔSAP-Mkl1 but not by mutB1-Mkl1, as
Table 1 SAP-dependent Mkl1 target genes
Gene Description Fold Reduction in
HC11-ΔSAP vs. HC11-FL cells
Functions
Microarrays
in 0.03% FCS
qRT-PCR in
0.03% FCS
qRT-PCR
in 3% FCS
SRF-independent genes
Tnc Tenascin C, ECM protein 3.07*** 3.50*** 26.34*** Cell adhesion, cell migration, wound healing and tissue
remodeling, cancer cell invasion and metastasis [10]
Anln Anillin, actin binding protein 3.10*** 1.93*** 1.38** Cell cycle regulation [26], cell motility and cancer
progression [26-28]
Nox4 NADPH oxidase 4 3.31*** 94.19** 332.70*** Cell growth, differentiation and migration [29], tumor
angiogenesis [30]
Adamts16 Metallopeptidase, ECM protein 3.63*** 5.70*** 14.84** Cell growth and motility [31], role in arthritis [32] and cancer
[31]
Krt5 Keratin 5, intermediate filament
protein
3.73*** 2.74*** 8.02*** Protein synthesis, epithelial cell growth and
differentiation [33,34]
p15 (PAF) 2810417H13Rik,
PCNA-associated factor
3.91*** 1.89*** 1.34*** DNA repair and cell cycle regulation, cell survival and
proliferation, tumorigenesis [35-37], hematopoiesis [38]
Ass1 Argininosuccinate synthetase 1 4.23*** 3.89** 2.72** Regulation of nitric oxide production and cell viability [39,40]
Cd34 CD34 antigen, stem cell antigen 4.25*** 10.61*** 1.72*** Vessel development and function [41], tumor growth [42,43]
Wisp1 WNT1 inducible signaling
pathway protein 1, ECM protein
4.41*** 2.54** 4.06** Cell proliferation and survival, ECM deposition and turnover,
EMT, tumorigenesis, tissue remodeling [44]
Mcm6 Minichromosome maintenance
complex component 6
4.42*** 2.83*** 1.30*** Cell cycle regulation [45]
Car12 Carbonic anyhydrase 12 4.58*** 16.11*** 26.07** Cell survival under hypoxic conditions, tumor-associated cell
migration and invasion [46,47]
Htatip2 Hyaluronectin, TIP30,
transcriptional regulator
5.89*** 548.59*** 245.27*** Regulation of apoptosis [48], tumor growth and
metastasis [49]
Kif26b Kinesin family member 26B 6.33*** 8.36*** 61.22*** Regulation of adhesion and cell polarity in kidney
development [50]
SRF-dependent genes
Lox Lysyl oxidase, ECM protein 4.61*** 4.70** 12.04*** ECM turnover, connective tissue remodeling and repair,
tumor progression and metastasis [51,52]
Mmp12 Matrix metallopeptidase 12,
metalloelastase
12.01*** 23.49*** 4.90** ECM degradation in tissue remodeling [49] and
tumorigenesis [53]
Mmp3 Matrix metallopeptidase 3,
stromelysin-1
15.64*** 14.70*** 2.08** ECM degradation in tissue remodeling [49] and
tumorigenesis [54]
Abbreviations: ECM extracellular matrix protein, PCNA proliferating cell nuclear antigen, EMT epithelial-to-mesenchymal transition.
***P < 0.001, **P < 0.01, Student’s t test.
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promoters that revealed SAP-dependency were shortened
to 200 bp upstream of the TSS to test whether this was
sufficient to relay the Mkl1 response, as it has been seen
previously for tenascin-C [13]. With the exception of Krt5
and Nox4, for which some activity was lost by shortening
the promoters, the 200 bp proximal promoters of all other
genes tested were induced equally well as the longer con-
structs (Figure 2B). Thus, we conclude that there are many
genes that are regulated similarly as tenascin-C requiring
the SAP domain of Mkl1 to induce transcription from
their proximal promoter.
The different HC11 cell strains proliferate at different
rates and show distinct migration behaviors
Next, we tested whether the differential gene expression
seen in the different HC11 strains overexpressing either
FL-, mutB1- or ΔSAP-Mkl1 constructs have functional
consequences on their behavior. Since most of the SAP-
dependent transcripts are proposed to have a function
in cancer, we decided to analyze two main functions im-
portant for cancer progression: proliferation and cell mi-
gration. An approximately equal overexpression of the
different Mkl1 protein variants in the HC11 cell lines was
confirmed by Western blot analysis (Figure 3A). An HC11
cell strain stably transfected with an empty vector [13]
expressing only endogenous Mkl1 (below the detection
limit in Figure 3A) was also included in these studies.
The proliferation rates of the HC11 strains were ana-
lyzed using a 5-bromo-2′-deoxyuridine (BrdU) incorp-
oration assay. The incorporated BrdU was measured
immediately after plating (0 h) as well as at 24, 48, 72
and 96 h. Compared to empty vector-, FL- or mutB1-
transfected HC11 strains, there was a significant decrease
in BrdU uptake into newly synthesized DNA in HC11-
ΔSAP cells over the entire time period tested (Figure 3B).
To investigate cell motility, we used a transfilter migration
assay. Similarly to the effect on cellular proliferation, the
expression of ΔSAP-Mkl1 significantly inhibited HC11 cell
migration by 2.7-fold compared to endogenous or full
length Mkl1 expression, and more than 3.5-fold compared
to mutB1-Mkl1 expression (Figure 3C).
Thus, overexpression of FL-Mkl1 protein in HC11
cells did not affect their behavior. However, overexpres-
sion of ΔSAP-Mkl1 led to a significant reduction in the
proliferative and migratory ability of HC11 epithelial cells,
either through a dominant-negative effect of ΔSAP-Mkl1
on SRF-mediated action and/or a positive impact of the
SAP-dependent Mkl1 target genes on these functions
important for cancer progression.
SAP-dependent Mkl1 target genes are
mechanoresponsive
We have previously found that the SAP-dependent in-
duction of tenascin-C was triggered by applying mech-
anical strain to fibroblasts. Mammary epithelial cells are
also exposed to mechanical strains, both during normal
development, pregnancy and lactation, as well as under
pathological conditions such as in cancer. Therefore, we
Figure 2 SRF-independent/SAP-dependent transcripts represent
direct Mkl1 target genes requiring the SAP domain of Mkl1 to
induce transcription from their proximal promoter. (A) The
indicated promoter constructs that contained at least 500 bp
upstream of the transcription start site (TSS) and were linked to the
secreted alkaline phosphatase (SEAP) reporter gene, were
cotransfected in HC11 cells together with an inactive Mkl1 devoid of
the transactivation domain [13] or the FL-Mkl1 construct. SEAP activity
is expressed as fold induction above the level obtained with the
inactive Mkl1. In addition to Tnc, for 8 out of the 12 new promoters
tested, induction greater than 2-fold (indicated by the red line) was
obtained. Values are means±SEM from three to seven independent
experiments. (B) HC11 cells were cotransfected with the indicated
promoter constructs that were either>500 bp or shortened to 200 bp
upstream of the TSS, and with vectors encoding the indicated mutant
Mkl1 constructs. SEAP activity is normalized and expressed as in
(A). Means±SEM from at least three independent experiments and
significant differences between either mutB1- and ΔSAP-Mkl1-
transactivated promoter constructs or between the longer and shorter
promoter constructs transactivated by mutB1-Mkl1, ***P<0.001,
**P<0.01,*P<0.05areshow n.
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SAP-dependent Mkl1-induced gene set are mechanore-
sponsive in HC11 cells. We tested two paradigms: 1) static
strain that was shown to induce c-fos, a very prominent
mechanoresponsive gene in HC11 cells [57] that we used
as a control, and 2) cyclic strain. While we were able to
confirm induction of c-fos by applying static strain at 20%
for 1 h, there was no induction of tenascin-C under these
conditions compared to cells at rest (Figure 4A). However,
using 15% cyclic strain at a frequency of 0.3 Hz for 1 h, we
found that not only the control gene c-fos but 11 out of
16 SAP-dependent genes, including tenascin-C were sig-
nificantly upregulated above the expression levels obtained
in resting cells (Figure 4). Even though significant, the in-
duction of tenascin-C was minimal (Figure 4A) compared
to 18-fold upregulation for Adamts16 or 10-fold upreg-
ulation for Lox (Figure 4B), both of which are enzymes
involved in extracellular matrix (ECM) remodeling and
cancer progression [31,58]. Being mechanoresponsive,
the SAP-dependent Mkl1 target genes might be activated
in stiff tumor tissue, which further confirms their relation
with cancer.
The SRF-independent/SAP-dependent genes represent a
bad prognostic signature for breast cancer patients
In order to investigate whether the SRF-independent/SAP-
dependent genes were prognostic of accelerated cancer pro-
gression in human patients, we used the bioinformatics tool
Gene expression-based Outcome for Breast cancer Online
(GOBO) that allowed us to investigate a breast tumor
data set containing 1881 samples analyzed by Affyme-
trix Human Genome U133A arrays. GOBO is designed
to assess gene expression levels and association with out-
come of single genes or gene sets in multiple subgroups of
Figure 3 The different HC11 cell strains proliferate at different
rates and show distinct migration behaviors. (A) Immunoblot
with mAb65F13 of Mkl1 proteins in whole-cell extracts from the
empty vector-, FL-, mutB1- or ΔSAP-transfected HC11 strains.
Anti-Gapdh served as loading control. Endogenous Mkl1 protein was
below the detection limit in empty vector cells. (B) SAP-dependent
proliferation of HC11 mammary epithelial cells. Proliferation rates of
the four HC11 cell strains were assessed by BrdU incorporation into
newly synthesized DNA immediately after plating (0 h) as well as at
24, 48, 72 and 96 h. Means±SD from three independent
experiments and significant differences to the HC11-ΔSAP cells,
***P<0.001, **P< 0.01, *P<0.05 are shown. (C) SAP-dependent
migration of HC11 mammary epithelial cells. Cell migration of the
four HC11 strains was evaluated by Transwell migration assay using
filters with 8 μm pore size. Quantification of the cell migration was
measured by the area on the lower side of the filter covered with
cells. Above the bar graph, a photo of fixed and stained cells seeded
in parallel in a 24-well plate is shown as a seeding control, and
representative photos of fixed and stained cells of each of the cell
strains that have migrated to the lower side of the filter, are shown
below (bar, 200 μm). Data and statistical significance are expressed
as in (B).
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sets of genes, namely the SRF/Mkl1-induced gene set
(SRF-dependent/SAP-independent) and the SAP-dependent
gene set (SRF-independent/SAP-dependent) containing
tenascin-C. The analysis was performed across tumor
samples stratified according to PAM50 subtypes [60],
estrogen receptor (ER)-status and histological grade. In
contrast to the SRF/Mkl1 target genes that were predom-
inantly associated with tumors classified as normal-like
and with lower histological grades (1 and 2) (Figure 5A),
elevated expression of SAP-dependent genes was associ-
ated with extremely high significance (P<0.00001) with
typical high-proliferative poor outcome classes in breast
cancer, such as basal-like, HER2-enriched, luminal B, ER-
negative and histological grade 3 tumors (Figure 5B). Next,
a functional correlation analysis to find a possible inter-
connection between the SAP-dependent Mkl1 target
genes was performed using the GOBO tool (Additional
file 4: Figure S3). This analysis explores the correlation
of expression of individual genes in our gene sets with
eight different co-expressed gene modules emulating
breast cancer-specific as well as general tumor biological
processes [61]. Interestingly, whereas the gene set of SRF/
Mkl1 targets did not show a significant correlation with
any of these modules, the genes in the SAP-dependent
gene set were correlated with a very high significance
(P<0.00001) with two proliferation modules – mitotic
checkpoint and mitotic progression. Both modules con-
tain genes related to central mitotic processes involved
in either the regulation of the M-phase and the mitotic
checkpoint or in carrying out the M-phase. Finally, the
association of our gene sets with outcome using distant
metastasis free survival (DMFS) as an endpoint and 10-
year censoring was analyzed. The survival analysis was
performed in all tumors for which DMFS follow-up is
available (1379 cases), as well as in 21 groups that were
stratified based on gene expression subtypes (PAM50
classifier), ER-status, lymph node (LN)-status, histological
grade, and treatment status. Samples in the whole cancer
data set (1881 patients) were stratified into three quan-
tiles, low, intermediate and high, based on SRF-dependent/
SAP-independent or SRF-independent/SAP-dependent gene
expression. Interestingly, high expression of SRF/Mkl1-
induced genes was associated with a better clinical out-
come for all tumors, as well as for LN-negative and
untreated tumors compared to low and intermediate ex-
pression of these genes (Figure 6A). In contrast, both high
and intermediate expression of the SAP-dependent genes
was associated with bad clinical outcome in all tumors,
and particularly in LN-negative, systemically untreated,
ER-positive, Grade 1 and 2 tumors (Figure 6B). Similar re-
sults were obtained for the typical breast cancer gene
CCNB1 by Ringnér et al. [59]. The Kaplan-Meier survival
analyses were supported by the corresponding multivariate
analyses (Figure 7A, B). The hazard ratio for the variate
Grade shows statistical significance, proving that the in-
fluence of high SAP-dependent gene expression on pa-
tient survival is independent of tumor grade. Among all
tumors for which DMFS data are available, a hazard ra-
tio of 0.44 (95% CI =0.28-0.68; P =0.0003) for the low
SRF-independent/SAP-dependent tercile was detected
compared to the high SRF-independent/SAP-dependent
tercile (Figure 7B, all tumors). This indicates that patients
Figure 4 SAP-dependent Mkl1 target genes are
mechanoresponsive. (A) Effect of static (20%) and cyclic (15%,
0.3 Hz) strain on Tnc and c-fos mRNA levels. HC11 cells were
cultured on either growth factor reduced matrigel matrix- or
fibronectin-coated silicone membranes in 0.03% serum-containing
medium for 24 h before applying static or cyclic strain for 1 h. Cells
cultured under the same conditions and not exposed to mechanical
stimulation were used as a resting control. The two types of coating
gave identical results under the indicated experimental conditions.
Total RNA was extracted and qRT-PCR was performed for Tnc and
c-fos mRNA levels. Values normalized to Gapdh are expressed
relative to the values of resting cells. Data represent means±SD
from three independent experiments. Significant differences to the
resting control, ***P<0.001, **P<0.01, *P<0.05. (B) SAP-dependent
genes respond to cyclic strain. HC11 cells were stretched and mRNA
analyses were performed as described in (A). Data and statistical
significance are expressed as in (A).
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genes are more than twice as likely to develop metastatic
disease. Similar hazard ratios, in the range of 0.28-0.44
for the low tercile compared to the high tercile were also
detected among subgroups of untreated, LN-negative,
ER-positive, Grade 1 and 2 tumors (Figure 7B). Thus,
the association of high SRF-independent/SAP-dependent
gene expression with reduced DMFS among patients not
receiving adjuvant therapy, as well as among LN-negative,
ER-positive, Grade 1 and 2 patients indicates that in-
creased expression of the SAP-dependent Mkl1 target
genes plays a significant role in the natural metastatic
progression of non-aggressive towards highly aggressive
breast cancer in human patients.
Discussion
Given the heterogeneity of mutations in tumor cells, it
becomes increasingly clear that not only individual
genes but pathways govern the course of tumorigenesis
and cancer progression [62]. We have recently shown
that induction of tenascin-C by cyclic mechanical strain
required the action of the potential DNA-binding SAP
domain of Mkl1 independently of an interaction of
Mkl1 with SRF [13]. Now, we report a screen for genes
co-regulated with tenascin-C by the same SAP-dependent
and SRF-independent mechanism in mammary epithelial
cells. This screen reveals a set of SAP domain-dependent
Mkl1 target genes with a strong implication in cell prolif-
eration, cell motility and cancer.
To date only a few studies have shown that Mkl1 is
implicated in cancer-related processes (reviewed in [63])
and most of them have concentrated on the SRF/Mkl1
signaling for the induction of individual genes [64-67].
The first study reporting that depletion of Mkl1/2 proteins
reduced motility, invasion and colonization of metastatic
tumor cells in an experimental in vivo metastasis assay
[64] was further supported by the discovery of the Mkl1-
binding protein, suppressor of cancer cell invasion (SCAI),
which inhibited SRF/Mkl1-mediated expression of β1i n -
tegrin [68]. Since then, several studies describing opposing
biological effects for Mkl1 appeared. For instance, several
antiproliferative SRF/Mkl1 target genes including mig6/
errfi-1, a negative regulator of the EGFR-MAPK pathway,
were identified [65], or the tumor suppressor gene Eplin-α
was described as a direct target of the SRF/Mkl1 path-
way [66]. Furthermore, expression of a constitutively ac-
tive form of Mkl1 in oncogenic ras- or src-transformed
rat intestinal epithelial cells injected into the spleen of
nude mice significantly suppressed tumor formation
and reduced liver metastases by rescuing the expression
of the SRF/Mkl1 targets tropomyosin and caldesmon
[67]. In line with these findings, we could show that
high expression of SRF/Mkl1 target genes is associated
with an improved clinical outcome in breast cancer pa-
tients. However, the opposite is the case for high expression
Figure 5 SAP-dependent Mkl1 target genes are associated with typical high-proliferative poor outcome classes in breast cancer. The
expression levels for the SRF-dependent/SAP-independent (A) and SRF-independent/SAP-dependent (B) gene sets are analyzed across the
1881-sample breast cancer data set stratified according to PAM50 subtypes (left panels), estrogen receptor (ER)-status (middle panels) and
histological grade (right panels), and represented by box plots using the GOBO bioinformatics tool. The number of tumors in each breast cancer
subtype and the significant difference in gene expression (P-value calculated using ANOVA) between them are shown above the box plots.
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ciated with poor clinical outcome predominantly in less ag-
gressive tumors such as LN-negative, ER-positive, Grade 1
and 2 tumors, which makes them valuable predictors of
breast cancer progression. A scheme that depicts our model
for Mkl1 action in breast cancer is presented in Figure 8. In
this model Mkl1 is transactivating SRF-target genes in less
aggressive tumors, while in the course of cancer progres-
sion and metastatic behavior Mkl1 is activating a new
group of genes in a SAP-dependent manner either by direct
Figure 6 The SRF-independent/SAP-dependent genes represent a bad prognostic signature for breast cancer patients. Tumors in the
1881-sample breast cancer data set were stratified into three quantiles, low, intermediate and high, based on SRF-dependent/SAP-independent
(A) or SRF-independent/SAP-dependent (B) gene expression. (A) Kaplan-Meier survival analysis using distant metastasis free survival (DMFS) as endpoint
and 10-year censoring for all tumors (n=1379; left panels), or in the subgroups of lymph node (LN)-negative (n=1111; middle panels) and untreated
tumors (n=821; right panels) was performed using the GOBO bioinformatics tool, interrogating the group of SRF-dependent/SAP-independent target
genes. P-value is calculated using log-rank test. (B) Kaplan-Meier survival analysis for tumors with expression of SRF-independent/SAP-dependent Mkl1
target genes was performed as in (A). Association with clinical outcome was assessed in the subgroups of ER-positive (n=856; left panel),
Grade 1 (n =141, middle panel) and Grade 2 (n= 446; right panel) tumors in addition to all tumors and the subgroups used in (A).P - v a l u ei s
calculated using log-rank test.
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action with additional DNA-binding factors.
Interestingly, in parental HC11 cells many of the genes
that we found in the SAP-dependent gene set that foster
cell proliferation and migration and may cause poor
survival of breast cancer patients are also induced by
mechanical strain. A recent study has demonstrated
that inhibition of cell spreading due to a lack of matrix
stiffness is overcome by externally applied stretch, sug-
gesting that similar mechanotransduction mechanisms
sense stiffness and stretch [69]. Tumor stroma is typically
stiffer than normal stroma. In breast cancer, diseased tis-
sue can be 10 times stiffer than normal breast [70,71]. It is
known that abnormal ECM stiffness plays an important
role in cancer progression [72,73], but the mechanisms by
which stiffness influences cancer progression are still
under investigation. If we assume that we have discovered
a general reaction of mammary epithelial cells to mechan-
ical strain, we envisage that epithelial cells in a stiff,
mechanically dynamic tumor environment may react by
inducing a SAP-dependent Mkl1 gene set that in turn
affects tumor progression. Furthermore, the products of
these genes, many of which are involved in ECM turn-
over and function, for example Lox [58], Mmps [74],
Adamts16 [31] or Wisp1 [44] might themselves manipu-
late the tumor microenvironment, thereby influencing
tumor cell survival by a positive tumorigenic feedback
loop.
Finding how to switch the mode of action of Mkl1 be-
tween SRF transactivation versus its SAP-dependent
transcriptional activity is a subject of ongoing research
in our lab that in future may help with the development
of new therapeutic interventions for breast cancer. Post-
translational modifications such as sumoylation are known
to influence Mkl1 transcriptional activity [75] and phos-
phorylation has been shown to influence interaction of
Mkl1 with nuclear actin resulting in transcriptional
changes [76,77]. Further characterization of these and
Figure 7 Elevated expression of SAP-dependent Mkl1 target genes is a poor prognosis factor in breast cancer independent of histological
grade. Multivariate analysis supporting the Kaplan-Maier survival analysis (shown in Figure 6) for the SRF-dependent/SAP-independent (A) and
SRF-independent/SAP-dependent (B) gene sets, was performed using the GOBO bioinformatics tool. The analysis was executed for all tumors
(n =1379) and in the subgroups of LN-negative (n= 1111) and untreated tumors (n =821) (A, B), as well as in the subgroups of ER-positive
(n =856), Grade 1 (n=141) and Grade 2 (n=446) tumors (B), using LN-status, ER-status, and stratified histological grade (histological grade 1
and 2 vs. 3) as covariates, DMFS as endpoint and 10-year censoring. The hazard ratio and the 95% confidence interval (CI) are plotted for each
of these covariates. Specified covariates may be omitted in certain comparisons, e.g. ER-status is omitted when analyzing ER-positive tumors
only, or when not all of the investigated cases have clinical follow-up or clinical information for the specified covariate.
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cial attention when trying to answer the above question.
Conclusions
In the current study, we discovered a breast cancer-
specific set of genes that is highly interesting as a prog-
nostic marker and therapeutic target for several reasons.
(1) The expression of this gene set is regulated by Mkl1
and its SAP domain and is independent of SRF. (2) The
SAP-dependent, SRF-independent Mkl1signaling is trig-
gered by mechanical strain and may thus be activated in
stiff tumors with a high stromal content and high inter-
stitial tissue pressure. (3) This gene set is composed of
interesting members some of which represent novel
candidates for playing a functional role in cancer and
others that have already been implicated in cancer-
related functions, as for example tenascin-C, a meta-
static niche component important for lung colonization
[8], or Lox as a gene mediating collagen crosslinking re-
sponsible for fibrosis-enhanced metastasis [58]. (4) The
SAP-dependent Mkl1 target genes are associated with a
poor clinical outcome in breast cancer patients, not re-
ceiving adjuvant therapy or having a cancer classified
as non-aggressive such as LN-negative, ER-positive,
Grade 1 or 2 tumors. This makes these genes potential
valuable prognostic markers in selecting patients who
may benefit from an immediate and/or more aggressive
therapy.
Methods
Cell culture
Full length Mkl1 (FL-Mkl1) and the two Mkl1 mutants,
mutB1-Mkl1 comprising alanine substitutions of four
amino acids (underlined) in the B1 domain of Mkl1 (KKA
KELKPKVKKLKYHQYIPPDQKQD) [78] and ΔSAP-Mkl1
with a deletion of the SAP domain [15], were constructed
based on transcript variant 1 (GenBank accession num-
ber NM_153049) as previously described [13]. All Mkl1
variants were expressed as C-terminal RFP-tagged fusions.
An empty vector expressing RFP alone was previously
described [13].
HC11 mammary epithelial cells, kindly provided by
Dr. N. Hynes (Basel, Switzerland), were grown in RPMI-
1640 medium supplemented with 10% FCS, 5 μg/ml insu-
lin (Sigma, Buchs, Switzerland) and 10 ng/ml epidermal
growth factor (EGF; Invitrogen, Zug, Switzerland). In most
of the experiments, the HC11 cells were starved in 0.03%
FCS/RPMI without EGF. To obtain HC11 cells stably
expressing FL-Mkl1-RFP (HC11-FL), mutB1-Mkl1-RFP
(HC11-mutB1), ΔSAP-Mkl1-RFP (HC11-ΔSAP) or RFP
alone (HC11-empty vector), cells were transfected using
FuGENE® 6 (Roche, Basel, Switzerland) and selected
Figure 8 Schematic representation of the Mkl1 action in breast cancer. A circular Mkl1 model is depicted with four of its domains: RPEL,
actin binding motifs with RPxxxEL core consensus; B1, basic domain involved in SRF-binding; SAP, homology domain found in the nuclear
proteins SAF-A/B, Acinus, PIAS; TAD, transactivation domain. Serum response factor is drawn as a red shape and putative unidentified
DNA-binding proteins as white shape with a question mark. Mkl1 exerts two distinct modes of action: one of them is through the B1 domain
required for serum response factor (SRF)-binding activity and induction of SRF/Mkl1 target gene expression; the other one is strongly dependent
on the SAP domain and triggers the expression of a specific set of pro-proliferative and pro-migratory genes that we called SAP-dependent Mkl1
target genes. High expression of SRF-dependent genes is associated with good clinical outcome for breast cancer patients, whereas elevated
expression of SAP-dependent targets correlates with poor prognosis and indicates a significant role for these genes in breast cancer progression.
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fluorescence-activated cell sorting (FACS) of RFP-positive
cells on aVantage SE (Becton Dickinson, Basel, Switzerland).
Cell viability of the four HC11 cell strains was assessed by
the CellTiter-Blue viability assay (Promega, Duebendorf,
Switzerland).
Cell proliferation assay
Proliferation rates of the HC11 cell strains were determined
using BrdU incorporation assay (Roche). After 24 h of star-
vation, cells were plated in triplicate on Black 96-well mi-
crotiter plates (PerkinElmer, Schwerzenbach, Switzerland)
at 5 × 10
3 cells/well in 3% FCS/RPMI and allowed to pro-
liferate for 0, 24, 48, 72 and 96 h before labeling with BrdU
for 2 h. BrdU incorporation into newly synthesized DNA
was determined according to the manufacturer’s protocol
using a Luminometer Mithras LB940 (Berthold Technolo-
gies, Regensdorf, Switzerland). Experimental values were
normalized to the values of HC11-ΔSAP cells at the time
point 0. Data represent means±SD from three independ-
ent experiments.
Cell migration assay
Cell migration was assayed using transwell polycarbonate
membrane inserts (6.5 mm; Corning, Amsterdam, The
Netherlands) with 8 μm pores as described [79]. After
24 h of starvation, 5 × 10
4 cells were plated in the top in-
sert chamber with 100 μl serum-free RPMI. The lower
chamber was filled with 600 μl 10% FCS/RPMI. Cells were
allowed to migrate across the filter for 22 h at 37°C before
fixation and crystal violet-staining. Images of duplicate in-
serts were acquired on a Nikon Eclipse E600 using 10×
magnification and a color CCD camera. Migration was
quantified by measuring the area covered by migrated cells
using the Fiji distribution of ImageJ [80]. Data represent
means±SD from three independent experiments.
Mechanical stimulation of cells
2×1 0
5 HC11 cells/well were seeded in BioFlex® 6-well
culture plates (Flexcell International, Hillsborough, NC,
USA) coated with either growth factor reduced-Matrigel
(BD Biosciences, Basel, Switzerland) or fibronectin [11].
Cultures were starved for 24 h before applying either
equibiaxial cyclic strain (15%, 0.3 Hz) or static strain
(20%) at 37°C for 1 h using Flexcell FX-4000 (Flexcell
International). Cells cultured under the same conditions
and not exposed to strain were used as a resting control.
After mechanical stimulation, cells were lysed and total
RNA was isolated using the RNeasy Mini Kit (Qiagen,
Basel, Switzerland).
Transcript profiling and bioinformatics analysis
HC11 cell strains stably expressing Mkl1 variants were
starved for 48 h before total RNA was extracted,
converted into labeled cDNA and hybridized to Affy-
metrix GeneChip Mouse Gene 1.0 ST arrays. RMA-
normalized expression values were calculated with the
Affy package from Bioconductor 2.4 [81], and differen-
tially expressed genes were identified using moderated
t-statistics calculated with the empirical Bayes method
as implemented in the Bioconductor limma package
[82]. To be considered as differentially expressed be-
tween HC11-FL and HC11-mutB1 or HC11-ΔSAP
cells, genes had to pass the filters: adjusted P-value≤
0.01 (with Benjamin-Hochberg false discovery correc-
tion), a minimum absolute linear fold change differ-
ence of 2.0 and a minimum average expression value of
4.0 (log2). Microarray data files are available from the
Gene Expression Omnibus (GEO; http://www.ncbi.nlm.
nih.gov/geo/), accession number GSE44907. Using the
above parameters, gene lists of the two contrasts (mutB1/
FL and ΔSAP/FL) were compared resulting in the forma-
tion of three gene groups: SRF-dependent/SAP-independ-
ent, SRF-dependent/SAP-dependent and SRF-independent/
SAP-dependent. The three gene sets were analyzed using
the bioinformatics softwares: 1) IPA (Ingenuity® Systems;
www.ingenuity.com); and 2) GOBO (http://co.bmc.lu.se/
gobo) [59]. In order to use the latter tool, Affymetrix Gene-
Chip Mouse Gene 1.0 ST IDs were mapped to Affymetrix
Human Genome U133A IDs using Biomart for Ensembl
build 66. The module “Gene Set Analysis Tumors” was
used to investigate the expression pattern and to per-
form survival and functional correlation analyses for the
SRF-dependent/SAP-independent and SRF-independent/
SAP-dependent gene sets across 1881 breast cancers char-
acterized by Affymetrix Human Genome U133A arrays.
RNA analyses by qRT-PCR
Total RNA was isolated from HC11 cell strains after
24 h of incubation either in 0.03 or 3% FCS/RPMI.
RNA was reverse transcribed and relative tenascin-C
and c-fos mRNA levels were detected as described
[12,13]. Relative mRNA levels for the genes listed in
Table 1, normalized to Gapdh, were measured using
Platinum® SYBR® Green qPCR SuperMix-UDG with
ROX (Invitrogen) and the primers listed in Additional
file 4: Table S4. Real-time PCR was performed in a Ste-
pOnePlus Real-Time PCR System (Applied Biosystems,
Rotkreuz, Switzerland) using a standard cycling profile.
All samples were run in duplicate. Data were analyzed
by the ΔCt method [83] and presented as fold changes
in mRNA expression levels between HC11-FL and
HC11-ΔSAP cells. RNA from stretched cells was ana-
lyzed by qRT-PCR using the efficiency ΔΔCt method
[84] that included a further normalization to the rest-
ing control. Data represent means± SD from three in-
dependent experiments.
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After 24 h of starvation, whole-cell extracts from the
three HC11 strains were prepared in RIPA buffer and
immunoblotting was performed as described [12,13].
The following primary antibodies were used: mAb65F13
anti-Mkl1 [12], MTn12 anti-Tnc [85], anti-Wisp1/CCN4
(clone 214203, R&D Systems), anti-Nox4 (NB110-58851,
Novus Biologicals), anti-Vcl (clone hVIN-1, Sigma) and
anti-Gapdh (ab9485, Abcam).
After reaching 90% confluency, HC11 strains were
starved for 48 h before conditioned medium was col-
lected, concentrated and analyzed by zymography as
described [86].
Promoter-reporter assays
The tenascin-C promoter used in this study was described
as TNC 247 bp [13]. Promoters of Acta2 [87] and all SRF-
independent/SAP-dependent genes described in Table 1
were PCR-amplified from genomic DNA and corresponded
to the sequences listed in Additional file 4: Table S5. Each
promoter contained≥500 bp 5′ of the TSS and was cloned
into the pSEAP2-Basic (Clontech, Saint-Germain-en-Laye,
France). For some promoters also 200 bp proximal pro-
moter sequences were cloned as described above. All clones
were verified by DNA sequencing.
HC11 cells in 6-well plates were cotransfected with
1 μg of the SEAP reporter vectors, 1 μg of pcDNA3 vectors
encoding Mkl1 variants [13], and 200 ng of the secreted
luciferase MetLuc vector (Clontech) used to normalize
for transfection efficiency. Cells were cultured in 0.03%
FCS/RPMI for 24 h before enzymatic activity measure-
ments were performed as described [13]. Experimental
values represent averages of three independent experi-
ments, each performed in duplicate.
Statistical analysis
Numerical results were expressed as means± SD. Stat-
istical analysis was completed using GraphPad InStat
Software, version 3.05. The two-tailed Student’s t test
was used to evaluate differences between two groups.
Multiple comparisons were performed using one-way
analysis of variance (ANOVA). Values of P less than 0.05
were considered statistically significant. Statistics for bio-
informatics analyses is given in figure legends.
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constructs. Figure S1. Quantification of SAP-dependent Mkl1 target gene
expression using qRT-PCR analysis. Figure S2. Differential expression of
newly discovered Mkl1 target genes in HC11 strains overexpressing either
FL-, mutB1- or ΔSAP-Mkl1 constructs (protein analyses performed by
immunoblotting and zymography). Figure S3. SAP-dependent Mkl1
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with the two proliferation modules – mitotic checkpoint and mitotic
progression (a functional correlation analysis performed using the GOBO
bioinformatics tool).
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